Priority Review Criteria Reassessment Called For In FDA Rezulin Report
Executive Summary
FDA's criteria for assigning priority review status should be re-evaluated, a Center for Drug Evaluation & Research Quality Assurance Staff report on the review of Warner-Lambert's Rezulin suggests.
You may also be interested in...
Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.
FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.
Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.
FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Glaxo Wellcome's withdrawal of Lotronex suggests that hurdles remain in FDA's efforts to expand the use of risk management programs for approved products.